The Current Ratio as of December 2025 (TTM) for Rapport Therapeutics, Inc. Common Stock (RAPP) is 36.37

According to Rapport Therapeutics, Inc. Common Stock’s latest financial reports and current stock price. The company's current Current Ratio is 36.37. This represents a change of 15.95% compared to the average of 31.37 of the last 4 quarters.

Rapport Therapeutics, Inc. Common Stock (RAPP) Historical Current Ratio (quarterly & annually)

How has RAPP Current Ratio performed in the past?

The mean historical Current Ratio of Rapport Therapeutics, Inc. Common Stock over the last ten years is 23.76. The current 36.37 Current Ratio has changed 15.21% with respect to the historical average. Over the past ten years (40 quarters), RAPP's Current Ratio was at its highest in in the September 2024 quarter at 45.91. The Current Ratio was at its lowest in in the March 2023 quarter at 0.

Rapport Therapeutics, Inc. Common Stock (RAPP) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Rapport Therapeutics, Inc. Common Stock Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Rapport Therapeutics, Inc. Common Stock (RAPP) Average Current Ratio

How has RAPP Current Ratio performed in the past?

The current Current Ratio of Rapport Therapeutics, Inc. Common Stock (RAPP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Rapport Therapeutics, Inc. Common Stock (RAPP) Current Ratio vs. Peers

How is RAPP’s Current Ratio compared to its peers?

Rapport Therapeutics, Inc. Common Stock’s Current Ratio is greater than Nurix Therapeutics, Inc. (5.35), greater than Kodiak Sciences Inc. (1.78), greater than Phathom Pharmaceuticals, Inc. (2.23), greater than Xencor, Inc. (5.34), greater than BridgeBio Oncology Therapeutics Inc. (13.33), greater than AnaptysBio, Inc. (8.68), greater than Mind Medicine (MindMed) Inc. (3.30), greater than UroGen Pharma Ltd. (4.14), greater than Oculis Holding AG (4.55), greater than Septerna, Inc. (6.53),

Build a custom stock screener for Rapport Therapeutics, Inc. Common Stock (RAPP) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rapport Therapeutics, Inc. Common Stock using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Rapport Therapeutics, Inc. Common Stock (RAPP) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Rapport Therapeutics, Inc. Common Stock or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.